A Clinical Study Conducted in Multiple Centers Evaluating Escalating Doses of Veliparib in Combination With Capecitabine and Radiation in Patients With Locally Advanced Rectal Cancer

Inclusion Criteria: * Subject must be ≥ 18 years of age * All subjects must have newly diagnosed, histologically proven adenocarcinoma of the rectum * All subjects must have an abdominal/pelvis computed tomography (CT ) scan or magnetic resonance imaging (MRI) confirming no evidence of distant metastases * Distal border of tumor \< 12 cm from anal verge * Subjects must have an Eastern Cooperative Oncology Group (ECOG) Performance Score of 0 to 2 * No prior treatment for LARC however prior treatments for other cancers are acceptable as long as they are considered curative Exclusion Criteria: * Subject is an unsuitable candidate for TME surgery * Subject has received anticancer therapy * Subject has received prior radiation therapy * Subject has had major surgery within 28 days prior to the first dose of study drug * History of gastric surgery, vagotomy, bowel resection or any surgical procedure that might interfere with gastrointestinal motility, pH or absorption